Brent Griffith
YOU?
Author Swipe
View article: IMG-33. Unveiling glioblastoma heterogeneity with deep learning derived MRI subtyping: insights from the global ReSPOND consortium
IMG-33. Unveiling glioblastoma heterogeneity with deep learning derived MRI subtyping: insights from the global ReSPOND consortium Open
PURPOSE This study aims to identify distinct imaging subtypes of glioblastoma using multi-modal MRIs from the ReSPOND consortium, providing insights into tumor heterogeneity to inform personalized treatment approaches. METHODS We analyzed …
View article: EPCO-09. INTEGRATIVE MODELING OF EPIGENETIC AND MRI FEATURES IN MENINGIOMA PROGNOSTICATION
EPCO-09. INTEGRATIVE MODELING OF EPIGENETIC AND MRI FEATURES IN MENINGIOMA PROGNOSTICATION Open
Meningiomas are the most common CNS tumors and are often benign, but a subset recurs or behaves aggressively. Traditional grading systems and imaging features have limited accuracy in predicting recurrence. Prior work, including ours, has …
View article: Sex-Specific Differences in Patients with<i>IDH1</i>–Wild-Type Grade 4 Glioma in the ReSPOND Consortium
Sex-Specific Differences in Patients with<i>IDH1</i>–Wild-Type Grade 4 Glioma in the ReSPOND Consortium Open
Our study demonstrates significant sex-based differences in clinical and radiologic tumor parameters of patients with glioblastoma. Sex is not an independent prognostic factor for survival outcomes and the tumor parameters influencing pati…
View article: Temporalis Muscle Thickness as a Prognostic Factor for 30-day, 90-day, and Overall Mortality in Newly-Diagnosed Glioblastoma
Temporalis Muscle Thickness as a Prognostic Factor for 30-day, 90-day, and Overall Mortality in Newly-Diagnosed Glioblastoma Open
Background The identification of novel prognostic biomarkers for glioblastoma (GBM) can guide clinicians and patients in treatment approaches. Frailty, as measured by sarcopenia, has been proven to predict overall survival in other oncolog…
View article: The outcomes measured and reported in intracranial meningioma clinical trials: A systematic review
The outcomes measured and reported in intracranial meningioma clinical trials: A systematic review Open
Background Meningioma clinical trials have assessed interventions including surgery, radiotherapy, and pharmacotherapy. However, agreement does not exist on what, how, and when outcomes of interest should be measured. To do so would allow …
View article: The outcomes measured and reported in observational studies of incidental and untreated intracranial meningioma: A systematic review
The outcomes measured and reported in observational studies of incidental and untreated intracranial meningioma: A systematic review Open
Background The clinical management of patients with incidental intracranial meningioma varies markedly and is often based on clinician choice and observational data. Heterogeneous outcome measurement has likely hampered knowledge progress …
View article: NIMG-13. ROBUSTNESS OF PROGNOSTIC STRATIFICATION IN DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: INSIGHTS FROM THE RESPOND CONSORTIUM
NIMG-13. ROBUSTNESS OF PROGNOSTIC STRATIFICATION IN DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: INSIGHTS FROM THE RESPOND CONSORTIUM Open
PURPOSE Glioblastoma is the most prevalent primary malignant brain tumor in adults, with a median overall survival (OS) of approximately 15 months and only limited advancements in prognostication and survival prediction. This study aims to…
View article: EPID-15. SEX-SPECIFIC DIFFERENCES IN GLIOBLASTOMA IN THE RESPOND CONSORTIUM
EPID-15. SEX-SPECIFIC DIFFERENCES IN GLIOBLASTOMA IN THE RESPOND CONSORTIUM Open
AIM The goal of this study was to understand sex-specific differences in the molecular, clinical and radiological tumor parameters and survival outcomes of Glioblastoma (GBM) patients within the international GBM dataset, known as the ReSP…
View article: Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium
Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium Open
Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
View article: Persistent Peri-Ablation Blood-Brain Barrier Opening After Laser Interstitial Thermal Therapy for Brain Tumors
Persistent Peri-Ablation Blood-Brain Barrier Opening After Laser Interstitial Thermal Therapy for Brain Tumors Open
Purpose Laser interstitial thermal therapy (LITT) is a minimally invasive, image-guided, cytoreductive procedure to treat recurrent glioblastoma. This study implemented dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) methods…
View article: Figure S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Figure S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
The histopathologic feature that correlated most closely with the MRI finding of T2-FLAIR mismatch was the presence of numerous, highly packed microcysts with variable sizes that were noted in regions of moderate or low cell density. These…
View article: Table S5 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S5 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
RPPA results comparing protein levels between the IDHmut-Noncodel gliomas from the TCGA/TCIA cohort differentiated by the T2-FLAIR mismatch sign.
View article: Table S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
Independent reader data and inter-reader agreement for the MRI features of the 125 LGGs from the TCGA/TCIA database.
View article: Table S4 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S4 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
RPPA results comparing protein levels between the 125 TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign.
View article: Figure S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Figure S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
Kaplan-Meier curves demonstrating progression free survival and overall survival associated with the LGGs from the TCGA/TCIA database. Blue curves represent IDHmut-Codel gliomas, dotted black curves represent IDHmut-Noncodel gliomas that w…
View article: Figure S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Figure S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
Kaplan-Meier curves demonstrating progression free survival and overall survival associated with the LGGs from the TCGA/TCIA database. Blue curves represent IDHmut-Codel gliomas, dotted black curves represent IDHmut-Noncodel gliomas that w…
View article: Data from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Data from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
Purpose: Lower-grade gliomas (WHO grade II/III) have been classified into clinically relevant molecular subtypes based on IDH and 1p/19q mutation status. The purpose was to investigate whether T2/FLAIR MRI features could distinguish betwee…
View article: Table S3 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S3 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
GSEA results comparing gene pathway expression differences between the IDHmut-Noncodel TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign. ES = Enrichment Score. NES = Normalized Enrichment Score. NOM = Nominal. FDR = False Dis…
View article: Table S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
GSEA results comparing gene pathway expression differences between the 125 TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign. ES = Enrichment Score. NES = Normalized Enrichment Score. NOM = Nominal. FDR = False Discovery Rate.…
View article: Table S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
Independent reader data and inter-reader agreement for the MRI features of the 125 LGGs from the TCGA/TCIA database.
View article: Table S5 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S5 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
RPPA results comparing protein levels between the IDHmut-Noncodel gliomas from the TCGA/TCIA cohort differentiated by the T2-FLAIR mismatch sign.
View article: Data from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Data from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
Purpose: Lower-grade gliomas (WHO grade II/III) have been classified into clinically relevant molecular subtypes based on IDH and 1p/19q mutation status. The purpose was to investigate whether T2/FLAIR MRI features could distinguish betwee…
View article: Table S4 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S4 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
RPPA results comparing protein levels between the 125 TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign.
View article: Figure S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Figure S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
The histopathologic feature that correlated most closely with the MRI finding of T2-FLAIR mismatch was the presence of numerous, highly packed microcysts with variable sizes that were noted in regions of moderate or low cell density. These…
View article: Table S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
GSEA results comparing gene pathway expression differences between the 125 TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign. ES = Enrichment Score. NES = Normalized Enrichment Score. NOM = Nominal. FDR = False Discovery Rate.…
View article: Table S3 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Table S3 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project Open
GSEA results comparing gene pathway expression differences between the IDHmut-Noncodel TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign. ES = Enrichment Score. NES = Normalized Enrichment Score. NOM = Nominal. FDR = False Dis…
View article: NIMG-29. ASSOCIATION OF PARTIAL T2-FLAIR MISMATCH SIGN AND ISOCITRATE DEHYDROGENASE MUTATION IN WHO GRADE 4 GLIOMA/GLIOBLASTOMA: RESULTS FROM THE RESPOND CONSORTIUM
NIMG-29. ASSOCIATION OF PARTIAL T2-FLAIR MISMATCH SIGN AND ISOCITRATE DEHYDROGENASE MUTATION IN WHO GRADE 4 GLIOMA/GLIOBLASTOMA: RESULTS FROM THE RESPOND CONSORTIUM Open
PURPOSE T2-FLAIR mismatch (T2FM) is a highly specific imaging biomarker for isocitrate dehydrogenase (IDH) mutation in low-grade gliomas. Previous T2FM studies are inconsistent for glioblastoma (GBM)/grade-4 glioma, partly due to low IDH-m…
View article: NIMG-33. PROGNOSTIC STRATIFICATION OF DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: UPDATES FROM THE RESPOND CONSORTIUM
NIMG-33. PROGNOSTIC STRATIFICATION OF DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: UPDATES FROM THE RESPOND CONSORTIUM Open
PURPOSE Glioblastoma, IDH-wildtype, is the most common primary malignant adult brain tumor with median overall survival (OS) of ~14 months, with little improvement over the last 20 years. We hypothesize that AI-based integration of quantit…
View article: NIMG-67. MULTI-PARAMETRIC MRI-BASED MACHINE LEARNING ANALYSIS FOR PREDICTION OF NEOPLASTIC INFILTRATION AND RECURRENCE IN PATIENTS WITH GLIOBLASTOMA: UPDATES FROM THE MULTI-INSTITUTIONAL RESPOND CONSORTIUM
NIMG-67. MULTI-PARAMETRIC MRI-BASED MACHINE LEARNING ANALYSIS FOR PREDICTION OF NEOPLASTIC INFILTRATION AND RECURRENCE IN PATIENTS WITH GLIOBLASTOMA: UPDATES FROM THE MULTI-INSTITUTIONAL RESPOND CONSORTIUM Open
PURPOSE Glioblastoma is extremely infiltrative with malignant cells extending beyond the enhancing rim where recurrence inevitably occurs, despite aggressive multimodal therapy. We hypothesize that important characteristics of peritumoral …